As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.
18 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:
18 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
|
| EBIT (Operating Income) EBIT | -29 -29 |
43%
43%
|
|
| Net Profit | -35 -35 |
73%
73%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
| Head office | United States |
| CEO | Wesley Kaupinen |
| Founded | 2001 |
| Website | palvellatx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


